1.68
—
Close of 6 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Grey Wolf Animal Health
Its shares trade on TSX Venture under the ticker WOLF.V. It has been listed since 17 June 2021. In the fiscal year to 31 December 2025, it reported revenue of C$35.8m and net income of C$1.7m. At that date it held total assets of C$64.5m and shareholders' equity of C$30.6m.
Grey Wolf Animal Health Corp. provides animal health care services. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-06-17. The company has a portfolio of products that meets the unmet needs of veterinarians, clinics, and pets. Its segments include the animal health business unit and the pharmacy business unit. The animal health business unit segment primarily focuses on selling, marketing, and distributing pharmaceutical, nutraceutical and consumable products to veterinary clinics across Canada. The pharmacy business unit segment compounds pharmaceuticals, primarily for equine use but also for the bioidentical hormone replacement therapy market, all based on prescriptions received from veterinarians, physicians, and patients. Its product categories include companion animals and equine health. The companion animals product category includes wound care, nutraceuticals, and others. The company focuses on in-licensing, acquiring, or developing prescription and non-prescription products for commercialization in the veterinarian channel in Canada.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 17 Jun 2021
- Website
- greywolfah.com ↗
Leadership
Pay as last reported
- Ms. Angela CechettoChief Executive Officer, SecretaryC$375,703
- Dr. Ian SandlerFounder, Director, Chief Veterinary Medical Officer, since 2022C$308,614
- Mr. Kevin PalmerChief Financial OfficerC$297,063
- Mr. Brandon Mair-wrenVice President - PharmacyC$265,319
- Mr. Shawn AspdenDirectorC$45,000
- Ms. Jill AngevineIndependent DirectorC$42,500
- Ms. Diane BourassaIndependent DirectorC$40,000
- Mr. Robert HarrisIndependent DirectorC$42,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Grey Wolf Animal Health Corp focuses on in-licensing and developing products for Canadian veterinary channels.
- The company's pharmacy business unit compounds pharmaceuticals for equine and bioidentical hormone markets based on prescriptions.
- Its animal health business unit distributes pharmaceuticals and nutraceuticals to veterinary clinics across Canada.
Weaknesses
- The company's pharmacy business unit is limited to prescription-based compounding for equine and hormone markets.
- Grey Wolf Animal Health Corp has no presence outside Canada in its animal health business unit.
- The company's product portfolio lacks expansion into non-veterinary markets beyond Canada.
Opportunities
- Grey Wolf Animal Health Corp can expand its pharmacy business unit into new prescription markets in Canada.
- The company has potential to grow its companion animal product category with wound care and nutraceuticals.
- Grey Wolf Animal Health Corp can leverage its in-licensing strategy to develop new products for Canadian veterinary channels.
Threats
- Grey Wolf Animal Health Corp faces competition from other animal health providers in Canada.
- The company's reliance on prescription-based compounding may limit growth in the pharmacy business unit.
- Regulatory changes in Canada could impact the distribution of pharmaceuticals to veterinary clinics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.